IDEAYA Biosciences, Inc. IDYA Net unrealized gains (losses) on securities still held
Net unrealized gains (losses) on securities still held at other companies
Other financials
Where this comes from
Reported directly by IDEAYA Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax.
The official record: IDEAYA Biosciences, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about IDEAYA Biosciences, Inc.'s net unrealized gains (losses) on securities still held.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is IDEAYA Biosciences, Inc.'s net unrealized gains (losses) on securities still held?
- IDEAYA Biosciences, Inc. (IDYA) reported net unrealized gains (losses) on securities still held of -$2.76M in Q1 2026.
- How has IDEAYA Biosciences, Inc.'s net unrealized gains (losses) on securities still held changed year-over-year?
- IDEAYA Biosciences, Inc.'s net unrealized gains (losses) on securities still held decreased by 457.2% year-over-year, from $773K to -$2.76M.
- What is the long-term trend for IDEAYA Biosciences, Inc.'s net unrealized gains (losses) on securities still held?
- Over 2 years (2021 to 2025), IDEAYA Biosciences, Inc.'s net unrealized gains (losses) on securities still held has grown at a 42.4% compound annual growth rate (CAGR), from -$718K to $1.46M.
- What does net unrealized gains (losses) on securities still held mean?
- This metric represents the change in the fair value of available-for-sale securities that have not yet been sold by the company. It captures fluctuations in the market value of investment portfolios that are recognized in equity rather than through the income statement. Monitoring this helps investors understand the potential impact of market volatility on the company's balance sheet and future liquidity.